Project Grant R01AI194953
Award Date 8/21/25
Completion Date 7/31/29
Dollars Obligated $3.2M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $605,895 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to Rutgers, The State University to conduct research on cryogenic nanoimaging of adeno-associated virus (AAV) infection and packaging. The project aims to directly observe key steps in AAV infection and transduction using cryo-electron microscopy techniques, in order to determine the structural basis for barriers...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $300,000 Project Grant under the Allergy and Infectious Diseases Research (CFDA 93.855) program to Optimeos Life Sciences, Inc., a biotechnology company in New Jersey. The grant supports the development of an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat severe immune deficiencies such as ADA-SCID. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $420,771 Project Grant to the Regents of the University of Minnesota, Office of Sponsored Projects Administration, under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The grant aims to develop targeted genetic therapies for Artemis-deficient severe combined immunodeficiency (ART-SCID), a rare and life-threatening primary immune disorder. The research focuses on using adenosine base...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $501,011.00 to the University of North Carolina at Chapel Hill to conduct research on biodegradable polymeric microparticles comprised of acetalated dextran and their ability to induce immune tolerance. The goal is to develop an antigen-specific tolerance therapy for autoimmune diseases, an alternative to general...
- This $444,125 federal Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Duke University. The funding supports research to simultaneously target immunoglobulin G and M antibodies using an endopeptidase enzyme, with the goal of overcoming humoral rejection in xenotransplantation. The research aims to provide a mechanistic explanation and intervention for the consistent early...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,937,578 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of North Carolina at Chapel Hill. The grant, awarded on August 18, 2025, supports the development of an ACE2 immunodecoy therapy for long-lasting immunoprophylaxis against SARS-CoV-2 variants and other zoonotic coronaviruses that target the human ACE2 receptor. The project aims to optimize the linkage...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $437,250 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Regents of the University of Minnesota for the project "Mingling Life Imaging and Cell Subpopulations Expression Analysis in NHP Lungs Targeted with Exosome Associated Double AAV Vectors". The project aims to advance gene therapy for lung diseases by using non-invasive in vivo imaging and post-necropsy...
- The federal Project Grant award of $3,436,588.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The award supports research to investigate the role of the TLE3 transcription cofactor in regulating the function and persistence of CD8+ T cells during chronic viral infections and cancer. The research aims to molecularly reconstruct the T cell exhaustion process and identify therapeutic...
- This federal Project Grant award of $658,657, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research at the University of Virginia on the biophysical and functional coupling of protein condensates to ordered lipid domains in T-cells. The research aims to reveal the mechanisms by which protein condensates and membrane domains cooperatively regulate T-cell signal transduction and...
- This $3,170,096 Project Grant was awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The grant supports research to develop the L7AE protein as a therapeutic for treating infections caused by the Orthomyxoviridae virus family, which includes influenza. The key research aims are: (1) investigating the mechanism of action of L7AE on various Orthomyxoviridae family members, (2)...